Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ingrezza in cervical dystonia
NCT05157100Phase 4Completed
- Sponsor
- The Orthopedic Foundation
- Start
- Oct 2021
- Primary completion
- Sep 2023
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of valbenazine in cervical dystonia (CD), sponsored by The Orthopedic Foundation. Primary endpoint: Change in incidence of pain/spasm at 16 weeks. Started Oct 2021; status: completed.
02
Drugs
valbenazine
03
Conditions
cervical dystonia (CD)
Beyond the preview
Go deeper on NCT05157100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05157100.